SN30000

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
024620102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Hypoxia is a prevalent feature of many tumors contributing to disease progression and treatment resistance, and therefore… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 4
  • table 2
Is this relevant?
2014
2014
SN30000 is a second-generation benzotriazine-N-oxide hypoxia-activated prodrug scheduled for clinical trial. Previously we showed… (More)
Is this relevant?
2014
2014
The radical species underlying the activity of the bioreductive anticancer prodrug, SN30000, have been identified by electron… (More)
Is this relevant?
2014
2014
SN30000 is a benzotriazine di-N-oxide which is selectively toxic to radio-resistant hypoxic cells in tumours. Given the complex… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2014
2014
The nitro-chloromethylbenzindoline prodrug SN29428 has been rationally designed to target tumour hypoxia. SN29428 is metabolised… (More)
Is this relevant?
2013
2013
UNLABELLED Hypoxia is a significant therapeutic problem for solid tumors because hypoxic cells are treatment-resistant and more… (More)
Is this relevant?
2012
2012
CEN-209 (SN30000) is a second-generation benzotriazine di-N-oxide currently in advanced preclinical development as a hypoxia… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
PURPOSE Benzotriazine-N-oxide bioreductive prodrugs such as tirapazamine and its improved analogue CEN-209 (SN30000) have… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2011
2011
e13597 Background: SN30000 (CEN-209), a benzotriazine-N-oxide, is a second generation analogue of tirapazamine (TPZ) and is… (More)
Is this relevant?
2010
2010
PURPOSE Tirapazamine (TPZ) has attractive features for targeting hypoxic cells in tumors but has limited clinical activity, in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?